Terms ending in 2035
Every in-force patent on Chemocentryx, Inc.'s record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,745,268 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 10,266,492 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 10,532,982 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,845,729 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 10,532,051 | Compositions and Methods for Treating Inflammatory Bowel Disease Using a Combination Therapy of Small Molecule Inhibitors of C-C Chemokine Receptor 9 (CCR9) and Anti-alpha4beta7 Integrin Blocking Antibodies In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,020,394 | Compositions and Methods for Treating Inflammatory Bowel Disease Using a Combination Therapy of Small Molecule Inhibitors of C-C Chemokine Receptor Type 9 (CCR9) and ANTI-ALPHA4BETA7 Integrin Blocking Antibodies In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,045,469 | Compositions and Methods for Treating Inflammatory Bowel Disease Using a Combination Therapy of Small Molecule Inhibitors of C-C Chemokine Receptor Type 9 (CCR9) and ANTI-ALPHA4BETA7 Integrin Blocking Antibodies In force · High confidence | ChemoCentryx, Inc. | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.